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Abstract 
The inhibitory effects of methanol, dichloromethane and aqueous extracts of Anogeissus leiocarpus (DC.) Guill. 
& Perr. and Terminalia glaucescens Planch ex Benth. (family Combretaceae) reportedly used in the treatment of 
gastrointestinal diseases including stomach disorder and ulcer are investigated to ascertain and justify their use in 
traditional medicine. Nineteen (19) strains of Helicobacter pylori including 18 clinical isolates and Helicobacter 
pylori ATCC 43504 were used in this study. The susceptibility and minimum inhibitory concentration (MIC) 
testing were performed using the agar dilution procedure guidelines of the Clinical and Laboratory Standards 
Institute. bactericidal studies were performed using viable counting techniques. The MIC and MBC values for 
the susceptible strains ranged from 0.08 mg/mL to 1.25 mg/mL and 0.16 mg/mL - 2.5 mg/mL respectively 
Bactericidal study revealed a dose- and time-dependent decline in surviving population of H. pylori AB005 at 
concentrations equivalent to MIC, 2 x MIC and 4 x MIC (Figures 1-4). The aqueous extracts of Anogeissus 
leiocarpus stem bark and root gave a 100% kill at 6-hour exposure time with concentration equivalent to 4x MIC 
(i.e. 0.32mg/mL). The antimicrobial activities demonstrated by extracts of the plants on Helicobacter pylori 
revealed the presence of therapeutically potent antibacterial compounds and thus justify the use of these 
medicinal plants for the treatment of peptic ulcer disease.  
Keywords: Anogeissus leiocarpus (DC.) Guill. & Perr.; Terminalia glaucescens Planch ex Benth.; Helicobacter 
pylori; peptic ulcer disease; bactericidal activity 
 
1. Introduction 
The use of medicinal plants for the cure of various diseases is very wide spread in many parts of the world 
including Nigeria among the rural population who cannot afford modern medicines which most often is beyond 
their reach. This practice involves the use of various plants/plant parts in different part of the world to treat 
human diseases and infections. Infection with Helicobacter pylori the aetiologic agent of gastritis, peptic ulcer 
disease (PUD), gastric MALT lymphoma and gastric cancer can be effectively treated with medicinal plants. 
Various medicinal plants have shown activity against Helicobacter pylori by successfully inhibiting its growth 
and multiplication in in vitro studies (Lawal et al., 2014a; Olorunnipa et al., 2013; Adeniyi et al., 2009; Mahady 
et al., 2005; 2003). In vivo studies have also been reported with significant reduction in bacterial load as well as 
inflammation in H. pylori-infected experimental animal models (Xie et al., 2013; Gaus et al., 2009). In our 
earlier study, we reported the anti-Helicobacter pylori activities of dichloromethane and methanol extracts of 
Myristica fragrans Houtt. seed (nutmeg) where culture and histopathological examinations revealed a clear 
reduction in the H. pylori colonization and mucosal inflammation and an increase in epithelial proliferation in 
the stomach of H. pylori-infected rats (Oyedemi et al., 2014).  
In this study, the inhibitory effects of Anogeissus leiocarpus (DC.) Guill. & Perr. and Terminalia 
glaucescens Planch ex Benth. (family Combretaceae) reportedly used in the treatment of gastrointestinal diseases 
including stomach disorder and ulcer are investigated to ascertain and justify their use in traditional medicine. 
Anogeissus leiocarpus (DC.) Guill. & Perr. is traditionally acclaimed to be effective in treating infectious 
wounds in man and animals (Dweek, 1996). The infusion and decoctions are used as cough medicine, the pulped 
roots are applied to wounds and ulcers (Ibrahim et al., 2005). In Côte d’Ivoire the fleshy roots are used against 
labour pains and in Burkina Faso to accelerate wound healing. The seeds have a wide bactericidal and fungicidal 
activity in humans and animals (Yahaya et al., 2008).  
The decoction of young leaves and the bark of Terminalia glaucescens are used for the treatment of 
stomach ache and abdominal pains. It is a valuable plant in the management of malaria; diarrhoea and tooth 
decay (Ojo et al., 2006). The leaf and bark find application in the treatment of naso-pharyngeal infections. The 
roots are used as medicines for the management of diarrhoea, dysentery, genital stimulants, depressants, leprosy 
and liver disorder (Burkill, 1985). The root bark enters a treatment for burns and for sores in general in Ivory 
Coast. In Ubangi-Shari root-bark is used on wounds and is said to have an effect like tincture of iodine 
(Mangaret et al., 1988). 
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2. Materials and Methods 
2.1 Plant collection, extraction and preparation of extracts 
Anogeissus leiocarpus (leaf, stem bark and root) and Terminalia glaucescens (root) plant materials were 
collected, identified with voucher specimens assigned FHI 109925 and FHI 108282 for Anogeissus leiocarpus 
and Terminalia glaucescens, respectively by the Forest Research Institute of Nigeria Ibadan, Oyo State (FRIN). 
Plant materials were extracted by cold maceration in methanol, dichloromethane and water. Methanol, 
dichloromethane and aqueous extracts of Anogeissus leiocarpus (DC.) Guill. & Perr. and Terminalia 
glaucescens Planch ex Benth.  were reconstituted in 0.5% DMSO to final concentrations at 20, 10, 2 and 1 
mg/mL. Lower concentrations in the range of 2.5 to 0.02 mg/mL were also prepared to determine the minimum 
inhibitory concentration (MIC) and the minimum bactericidal concentration of the bioactive extracts. 
 
2.2 Bacterial Isolates 
Nineteen (19) strains of Helicobacter pylori including 18 clinical isolates and Helicobacter pylori ATCC 43504 
were used in this study. The clinical isolates were H. pylori AB003, 005, 010, 012, 015, 018, 020, 021, 024, 025, 
026, 032, 033, 036, 037, 038, 042 and H. pylori AB044. The test organisms were subcultured from stored slopes 
at the Department of Pharmaceutical Microbiology Laboratory.  
 
2.3 Susceptibility Testing and Determination of Minimum Inhibitory Concentration 
The susceptibility and minimum inhibitory concentration (MIC) testing were performed using the agar dilution 
procedure guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2008). To 19 mL of sterile molten 
Mueller-Hinton agar supplemented with 5% defibrinated horse blood was added 1 mL of the extract. The final 
concentrations of the extracts tested were 20, 10, 2 and 1mg/mL reconstituted with 0.5% DMSO. MacFarland 2 
suspensions of H. pylori strains were prepared in Tryptic soy broth from 4–5 days old H. pylori on blood agar. 
The organisms were inoculated onto agar plates containing the plant extracts via a graduated inoculating device 
which delivers inoculum size of 1 x 104 cfu/mL per spot. The spots were air-dried before incubating the plates at 
37oC under a microaerophilic gas mixture composed of 10% CO2, 5% O2, and 85% N2 (Campygen, Oxoid, UK) 
at 100% humidity and examined for growth after 72 hours. Ciprofloxacin at 10µg/mL and 20µg/mL was used as 
positive control. All procedures were repeated for accuracy. The least concentration that gave no visible growth 
was taken as the minimum inhibitory concentration (MIC) of the extract.  
 
2.4 Determination of Minimum Bactericidal Concentration 
The minimum bactericidal concentration (MBC) testing was performed as previously described (Lawal et al., 
2014b). The lowest concentration that prevented bacterial growth after days of incubation was recorded as the 
minimum bactericidal concentration (MBC). All tests were performed in duplicates to ensure accuracy. 
 
2.5 Bactericidal Kinetics 
The bactericidal activity was performed using viable counting techniques previously described (Ogudo et al., 
2014). The concentrations of the extracts used for the kill kinetics were those corresponding to MIC, 2 x MIC 
and 4 x MIC for the aqueous extracts. Samples were withdrawn at zero minute (0 min), 0.5, 1, 2, 4, 6 hour and 
24 hours. The inoculum was evenly dispersed using sterile glass spreader. The drug control and solvent control 
ran simultaneously with the test. The plates were appropriately incubated for 24 hours after which the number of 
colonies on each plates were counted using Stuart scientific colony-counter. The number of survivors (cfu/mL) 
was calculated taking into consideration the final volume of inoculum plated out and the dilution factor. The 
results are the average of duplicate tests. A graph of viable count (Log10) against time (hour) was plotted to 
show the rate of kill of the test organism. 
 
3. Results and Discussion   
The use of medicinal plants in the treatment of gastrointestinal diseases including peptic ulcer diseases (PUD) in 
which Helicobacter pylori is implicated is becoming widespread due to the difficulty in the treatment choice of 
Helicobacter pylori infection. Treatment choice involving triple or quadruple combination of drugs do not often 
effect cure of the disease because healing of PUD is hinged on eradication of H. pylori. Thus, it has become 
increasingly necessary to look in the direction of alternative therapy involving natural remedies especially 
medicinal plants for the cure of H. pylori infections and resulting diseases. Hence, Anogeissus leiocarpus (DC.) 
Guill. & Perr. and Terminalia glaucescens Planch ex Benth. (family Combretaceae) identified from our 
ethnobotanical survey of plants used for the treatment of gastrointestinal diseases were evaluated for their 
inhibitory effects on Helicobacter pylori. Nineteen isolates of H. pylori were screened in the study out of which 
sixteen including H. pylori ATCC 43504 (CagA+ strain and a carcinogen) were susceptible to the methanol and 
aqueous extracts of the test plants with diameter of zone of inhibition ranging between 10 + 0.0 mm to 29 + 0.0 
mm (data not shown). The dichloromethane had little/no activity. Bioactive extracts were further tested to 
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determine the minimum inhibitory concentration (MIC), minimum bactericidal concentration as well as kill 
kinetics. The inhibition of H. pylori was dose-dependent as revealed by the diameter of zone of inhibition which 
at the highest concentration of 20 mg/mL compared favourably with clarithromycin (pure drug control) at 10 
µg/mL. The MIC and MBC values for the susceptible strains ranged from 0.08 mg/mL to 1.25 mg/mL and 0.16 
mg/mL - 2.5 mg/mL respectively (Table 1).  Bactericidal study revealed a dose- and time-dependent decline in 
surviving population when H. pylori AB005 was exposed to the aqueous extracts of both plants at concentrations 
equivalent to MIC, 2 x MIC and 4 x MIC (Figures 1-4). The aqueous extracts of Anogeissus leiocarpus stem 
bark and root gave a 100% kill at 6-hour exposure time with concentration equivalent to 4x MIC (i.e. 
0.32mg/mL). 
Although the mechanism(s) of action the aqueous extracts of Anogeissus leiocarpus and Terminalia 
glaucescens on H. pylori is/are not yet known, it is not unusual for the components of the extracts to act 
synergistically or additively to exert inhibitory effects on the test organisms. The phytochemical components 
found in these plants from our phytochemical screening were saponins, flavonoids, tannins, alkaloids, reducing 
sugar, glycosides and resins all of which are known to possess antimicrobial activities on a wide variety of 
microorganisms. This is similar to the report of Olajire and Azeez (2011). Terpenoidal fractions isolated from 
both Anogeissus leiocarpus (DC.) Guill. and Perr. (Stem) and Terminalia avicennioides Planch. (Root) were 
reported to possess antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas 
aeruginosa (Ibrahim et al., 2005). The leaves of Anogeissus leiocarpus contain ellagic, gallic and gentisic acids, 
derivatives of gallic and ellagic acid and several flavonoids (derivatives of quercetin and kaempferol). The high 
concentration (up to 17%, based on dry matter) of hydrolysable tannins (gallic and ellagic acid derivatives) 
explains the medicinal usefulness of Anogeissus leiocarpus (Kubmarawa et al., 2007). The leaf, stem and the 
root bark of Anogeissus leiocarpus have been reported to contain secondary metabolites such as alkaloids, 
saponins, flavonoids and glycosides; sterols and phenols were also isolated from its root bark (Mann et al., 2008). 
Terminalia species are known to contain several triterpenes, ellagic acid and derivatives of ellagic acid with 
broad spectrum antimicrobial activities (Dermarderosian, 2002). The inhibitory activities of Anogeissus 
leiocarpus and Terminalia glaucescens on Helicobacter pylori as revealed from our study compared fairly well 
with clarithromycin (a pure drug) and may well position these plants for further research to isolate and 
characterize the anti-Helicobacter pylori compound(s) which can be developed and/or modified to elicit better 
activity than the existing antibacterial agents currently used for the treatment of peptic ulcer disease. This is 
perhaps the first report on the anti-Helicobacter pylori effects of these plants. 
 
4. Conclusion 
The study investigated the antibacterial activity of Anogeissus leiocarpus (DC.) Guill. & Perr. and Terminalia 
glaucescens Planch ex Benth. (family Combretaceae) on nineteen strains of Helicobacter pylori including H. 
pylori ATCC 43504. The aqueous extracts of both plants were the most active on the test organisms supporting 
the use of these plants in folklore medicine where they are most often infused in hot water to administer to the 
patients for the treatment of various diseases including peptic ulcer disease. Although the mechanism of the 
inhibitory effects observed in these plants have not been studied, further research will focus on the mechanism of 
inhibitory activity as well as the anticancer effects of these plants on gastric cancer in which H. pylori has been 
implicated. 
Table 1: Minimum inhibitory concentration (MIC) (mg/mL) and minimum bactericidal concentration (MBC) 
(mg/mL) of aqueous extracts of Anogeissus leiocarpus and Terminalia glaucescens root on susceptible 
Helicobacter pylori strains 
Plant Sample Anogeissus 
leiocarpus Leaf  
Anogeissus 
leiocarpus Stem 
bark 
Anogeissus 
leiocarpus Root 
Terminalia 
glaucescens root 
Ciprofloxacin 
 (µg/mL) 
Organism MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
H.  pylori AB 005 0.625 1.25 0.08 0.16 0.08 0.625 0.08 0.16 10 10 
H.  pylori AB 010 0.08 0.625 0.16 1.25 0.08 0.625 0.32 0.32 5 10 
H.  pylori AB 012 0.08 0.16 0.08 1.25 0.08 1.25 0.32 0.625 10 10 
H.  pylori AB 018 0.16 0.32 0.08 0.16 0.08 0.08 0.08 0.16 5 10 
H.  pylori AB 020 0.625 0.625 1.25 2.5 0.32 0.625 0.625 0.32 5 10 
H.  pylori AB 021 0.08 0.16 0.08 0.625 0.08 0.32 0.32 0.16 5 10 
H.  pylori AB 024 0.08 0.16 0.08 1.25 0.16 0.32 0.32 0.32 5 10 
H.  pylori AB 026 0.16 0.32 0.16 0.32 0.16 0.32 0.32 0.625 5 5 
H.  pylori AB 036 0.16 0.32 0.08 0.16 0.08 0.08 0.08 0.16 5 5 
H.  pylori AB 038 0.08 0.16 0.08 0.32 0.08 0.32 0.32 0.32 5 10 
H.  pylori AB 042 1.25 0.16 0.32 0.16 0.625 1.25 1.25 0.16 10 20 
H.  pylori ATTC 
43504 
1.25 2.5 0.32 0.16 0.32 0.625 1.25 0.08 
5 10 
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Figure 1: Plot of Viable count (Log10) against Time (hour) of aqueous extract of Anogeissus leiocarpus leaf 
against Helicobacter pylori AB 005 showing the rate of kill at the different concentrations and exposure time. 
 
Figure 2: Plot of Viable count (Log10) against Time (hour) of aqueous extract of Anogeissus leiocarpus stem 
bark against Helicobacter pylori AB 005 showing the rate of kill at the different concentrations and exposure 
time. 
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Figure 3: Plot of Viable count (Log10) against Time (hour) of aqueous extract of Anogeissus leiocarpus root 
against Helicobacter pylori AB 005 showing the rate of kill at the different concentrations and exposure time. 
 
 
Figure 4: Plot of Viable count (Log10) against Time (hour) of aqueous extract of Terminalia glaucescens root 
against Helicobacter pylori AB 005 showing the rate of kill at the different concentrations and exposure time. 
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